JP Morgan Initiates Coverage of Enfusion Inc with Neutral Recommendation in 2023.

March 19, 2023

Trending News ☀️

JP Morgan recently initiated coverage of Enfusion ($NYSE:ENFN) Inc with a Neutral recommendation in 2023. This rating is based on JP Morgan’s assessment of Enfusion’s current operations and future prospects. JP Morgan noted that Enfusion has experienced steady growth in the past year and has made impressive progress in developing new products and services. They also acknowledged that the company has strong management and a solid financial position, but they feel that the stock’s current valuation is stretched. JP Morgan also noted that while Enfusion has made impressive strides in expanding its product offerings and operational capabilities, there are still significant risks associated with the company’s growth potential.

This includes potential issues with cash flow, competition in the market, and the potential for changes in regulatory environments. As such, JP Morgan believes that the company is currently trading at a premium and is unsure of its long-term prospects. Overall, JP Morgan’s initiation of coverage of Enfusion Inc with a Neutral recommendation serves as a reminder that while investors should be aware of the risks associated with investing in a growing and potentially volatile industry, they should also pay close attention to how the company is performing over time and how its future prospects may evolve. As such, investors should conduct further research into Enfusion before making any decisions about investing in the company.

Share Price

So far, the news about the company has been predominantly positive. On Thursday, the stock of ENFUSION opened at $10.9 and closed at $10.9, a slight 0.1% gain from the prior closing price of $10.9. This indicates investors may be reluctant to purchase ENFUSION shares at current levels. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Enfusion. More…

    Total Revenues Net Income Net Margin
    150.35 -8.61 -5.1%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Enfusion. More…

    Operations Investing Financing
    14.16 -7.93 -7.96
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Enfusion. More…

    Total Assets Total Liabilities Book Value Per Share
    123.78 20.34 0.92
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Enfusion are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    36.6% -8.0%
    FCF Margin ROE ROA
    4.1% -11.9% -6.0%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    GoodWhale has conducted an in-depth analysis of ENFUSION‘s fundamentals and we have found some interesting results. According to Star Chart, ENFUSION has a high health score of 8/10, which indicates that it is capable to safely ride out any crisis without the risk of bankruptcy, considering its cashflows and debt. Moreover, ENFUSION is strong in asset, growth, and medium in profitability, but weak in dividend. Based on this analysis, we have classified ENFUSION as a ‘cheetah’, which is a type of company that has achieved high revenue or earnings growth but is considered less stable due to lower profitability. Investors who are interested in such companies are typically those seeking a high return potential with a moderate degree of risk. These investors are likely to be willing to take some risks in order to reap the rewards of potential returns from ENFUSION’s growth opportunities. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    In the business world, there is always competition. Enfusion Inc is no exception. Its competitors, Redcastle Resources Ltd, WaveDancer Inc, FalconStor Software Inc, are all vying for the same market share. Enfusion Inc has the advantage of being a well-established company with a strong brand. Its competitors are relative newcomers and are still trying to establish themselves in the market. Enfusion Inc is also a market leader in its field, with a strong reputation for quality products and services. Its competitors are still trying to catch up.

    – Redcastle Resources Ltd ($ASX:RC1)

    Redcastle Resources Ltd is a Canadian mineral exploration company with a focus on gold and copper projects in North America. The company has a market capitalization of 4.92 million as of 2022 and a return on equity of -15.38%. The company’s primary project is the Redcastle Gold Project, located in British Columbia, Canada.

    – WaveDancer Inc ($NASDAQ:WAVD)

    WaveDancer Inc is a publicly traded company with a market capitalization of 17.49 million as of 2022. The company has a return on equity of -28.79%. WaveDancer Inc is a company that provides wave energy conversion technology and services.

    – FalconStor Software Inc ($OTCPK:FALC)

    FalconStor Software, Inc. is a software company, which provides data protection and storage management solutions. It offers various solutions for storage virtualization, storage replication, disaster recovery, continuous data protection, and cloud storage. The company was founded by ReiJane Huai and James J. Donovan in October 2000 and is headquartered in Austin, TX.


    Enfusion Inc. has been gaining significant attention in the investing world since its launch in 2023. Analysts at JP Morgan have recently initiated coverage of the company with a neutral recommendation. The majority of news about Enfusion Inc. so far has been positive, with investors attracted to its strong competitive advantages, innovative products and services, and impressive financial performance. Its well-rounded team of experienced management has been widely praised for their effective strategies.

    Despite the positive outlook, investors should be aware of potential risks such as rising competition, fluctuating market conditions, and the potential for regulatory changes. Overall, Enfusion Inc. is seen as a promising investment opportunity and one worth researching further.

    Recent Posts

    Leave a Comment